We will analyze the data with RevMan software (Version 5.3) (Available at: https://community.cochrane.org/help/tools-and-software/revman-5) provided by The Cochrane Collaboration.[18]A meta-analysis using random or fixed effects models will be conducted to summarize the data. Continuous data will be pooled and presented as mean differences or standardized mean difference with their 95% CI. Dichotomous data will be pooled and expressed as risk ratio with their 95% CI. We will interpret it using the following criteria: I2 values of 25% is considered low levels of heterogeneity, 50% indicated moderate levels, and 75% indicated high levels.[19] Since low or moderate heterogeneity suggests little variability among these studies, the data will be analyzed in a fixed-effects model.[20] When significant heterogeneity occurs among the studies (P < .05, I2 > 50%), a random-effect model will be performed to analyze the data.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.